Ok everyone, after some sleuthing, i have uncovered the abstract that was submitted to the IGCS conference
it is published in the international journal of gynecological cancer. The abstract only discusses the adverse events. I assume this is because price sensitive information cannot be published ahead of the company announcement. See below
63 patients enrolled. Median age was 55 yrs (range 34-75 yrs). Six serious adverse events (SAE) have occurred, four in the Cvac arm (transient hospitalization for bowel obstruction, two hospitalizations for disease progression (one prior to receipt of Cvac and a second related to surgery for disease progression), and febrile neutropenia after docetaxel treatment for disease progression). Two SAE occurred in the SOC (transient hospitalization for bowel obstruction, death due to cerebral hemorrhage). Cvac related adverse events included transient flu-like symptoms, fatigue and mild injection site reactions. Data on progression free survival at one year, and Cvac related T Cell activation will be presented at the meeting.
PRR Price at posting:
14.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)